Benchmark raises Halozyme stock price target to $90 on strong earnings

Halozyme Therapeutics (HALO) has received multiple analyst price target increases, including Benchmark to $90 and Citizens JMP to $91, alongside rating upgrades, following a significant Q2 2025 EPS beat and raised 2025 guidance, despite a revenue shortfall. While the company exhibits robust financial health with a 62% YTD return, the competitive landscape is intensifying due to Merck's FDA approval of Keytruda Qlex, which utilizes a competing enzyme, exacerbating ongoing patent litigation and creating a nuanced outlook for the stock.

Analysis

Halozyme Therapeutics is exhibiting a mix of strong positive catalysts and significant fundamental risks, leading to a wide dispersion in analyst ratings. On the positive side, the company's stock has seen a 62% year-to-date return and is trading near its 52-week high, supported by a perfect Piotroski Score of 9. This momentum is further fueled by a significant second-quarter 2025 earnings per share of $1.54, which beat expectations by 24.19%, and an upward revision to the company's 2025 financial guidance. Consequently, multiple firms have raised price targets, including Benchmark to $90 and Citizens JMP to $91. However, this bullish sentiment is sharply contrasted by a substantial revenue shortfall of 27.97% in the same quarter, with reported revenue of $206 million falling well short of the $286.01 million forecast. The primary headwind stems from intensifying competition and legal challenges; the recent FDA approval of Merck’s Keytruda Qlex utilizes a competing enzyme, which directly threatens Halozyme's Enhanze technology and is expected to escalate the ongoing patent litigation between the two companies. This complex outlook is reflected in the divergence of analyst opinions, from Morgan Stanley's 'Overweight' upgrade to Goldman Sachs' 'Neutral' rating with a more conservative $56 price target, which also considers potential regulatory impacts from the Inflation Reduction Act.

Key Decisions for Investors

• Investors should weigh the strong earnings momentum and upwardly revised guidance, which have driven multiple analyst upgrades, against the significant Q2 revenue miss that highlights underlying business pressures.
• The primary risk to monitor is the dual threat of intensifying patent litigation with Merck and the market penetration of the competing Keytruda Qlex formulation, as these factors could materially impact future royalty revenues from the Enhanze platform.
• Given the 62% YTD appreciation, it may be prudent to protect gains while remaining watchful for specific catalysts, such as outcomes from the Merck litigation or clarification on CMS guidance, which could either validate bullish price targets or justify the more cautious outlooks.